Lantheus price to book ratio LNTH
Market value divided by the book value of the company's net assets, since 2018.
- Today, Oct 23, 2026
- 5.0×
- 9-year median
- 5.8×
- Against its 9-year history
- 34th
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 1.4× to 29.3×
- Peer median
- 3.6×
Lantheus' price to book ratio is 5.0× as of Oct 23, 2026.
That is below its 9-year median of 5.8×, lower than on 66% of days in the last 9 years.
Over that time it ranged from 1.4× in Oct 2020 to 29.3× in Apr 2018.
The median for 10 diagnostics and research stocks of a similar size is 3.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.0× | 3.8× | 5.9× |
| 2025 | 4.0× | 2.9× | 6.8× |
| 2024 | 5.4× | 4.5× | 9.0× |
| 2023 | 6.1× | 5.2× | 15.3× |
| 2022 | 5.5× | 3.4× | 10.3× |
| 2021 | 3.9× | 1.9× | 4.1× |
| 2020 | 1.8× | 1.4× | 7.4× |
| 2019 | 7.9× | 7.8× | 13.9× |
| 2018 | 10.4× | 10.1× | 29.3× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Lantheus' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| LNTHLantheus | 5.0× |
| BLLNBillionToOne | 9.5× |
| CAICaris Life Sciences | 15.3× |
| BIOBio-Rad Laboratories | 1.4× |
| VCYTVeracyte | 2.8× |
| CDNACareDx | 8.4× |
| RVTYRevvity | 2.5× |
| MEDPMedpace | 43.1× |
| LHLabcorp | 3.1× |
| DGXQuest Diagnostics | 3.6× |
| MTDMettler-Toledo International | n/m |
| Peer median | 3.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Lantheus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.